 ISSN: **3107-6513**

# A Review Harnessing Artificial Intelligence for Enhanced Pharmacovigilance

CH.NAGA SOWJANA*[1] Dr. D RAMA BRAMHA REDDY*[2]
M.MANISHA*[3]

*[1] *Assisstant professor,pharmaceutics, nalanda institute of pharmaceutical Sciences, Sattenapalli, Kantepudi, Andhra Pradesh, India*

*[2]*Principal, Phytochemisry, pharmaceutical Sciences,* Sattenapalli*, Kantepudi, Andhra pradesh, India*

*[3]*Student, B. pharmacy, Nalanda Institute Of Pharmaceutical Sciences, Sattenapalli, Kantepudi, Andhra pradesh india*

## ABSTRACT

Pharmacovigilance (PV) plays a crucial role in ensuring drug safety by monitoring and assessing Adverse Drug Reactions (ADRs). However, the traditional methods of PV are often labor-intensive, time-consuming and limited by human capacity for data processing and analysis. Recent advancements in Artificial Intelligence (AI) present new opportunities to enhance PV activities, enabling more efficient and accurate detection, assessment and prevention of ADRs. This comprehensive review explores the integration of AI technologies, such as machine learning, natural language processing and data mining, into PV systems. It examines the potential of AI to automate the collection, analysis and interpretation of vast amounts of data from diverse sources, including electronic health records, social media and scientific literature. Furthermore, the review discusses the challenges and ethical considerations associated with AI implementation in PV, such as data privacy, algorithmic bias and the need for regulatory frameworks. By synthesizing current research and case studies, this review highlights the transformative potential of AI in PV and provides recommendations for future research and practice in this critical field

**KEYWORDS**: Pharmacovigilance, Artificial Intelligence, Adverse drug reactions,machine learning.

## INTRODUCTION

Pharmacovigilance (PV), originating from the terms "Pharmakon" and "vigilia," is a vital scientific discipline focused on monitoring medicinal products both before and after they reach the market. Its goal is to detect, evaluate and prevent adverse effects, medication errors and drug interactions, thereby ensuring safe drug usage. Despite challenges like underreporting adverse drug reactions, pharmacovigilance strives to enhance drug safety, improve reporting rates and reduce adverse drug reactions. Ultimately, it contribute assessing the benefit-risk profile of drugs, ensuring better patient safety and efficacy[1,2]

Artificial Intelligence (AI) encompasses a range of technologies aimed at mimicking human intelligence, including machine learning, natural language processing, neural networks, computer vision and robotics. Machine Learning (ML) focuses on analysing data to allow systems to learn from it, identify patterns and make decisions with minimal human intervention. Natural Language Processing (NLP) allows computers to understand, interpret and communicate in human languages. Neural networks, modeled after the human brain, utilise interconnected nodes to process information and recognize complex patterns. Computer vision employs pattern recognition and deep learning to analyse images and videos. Robotics focuses on creating and using robots, with AI empowering them to carry out tasks that require human-like intelligence[.[3,4]

Traditional methods of pharmacovigilance primarily involve Spontaneous Reporting Systems (SRS), literature reviews and casereports.However, these methods face challenges, such as underreporting, data duplication and the difficulty of processing large volumes of unstructured data, which can lead to delays in detecting potentialsafety issue.[5]

## ROLE OF ARTIFICIAL INTELLIGENCE IN PHARMACOVIGILANCE

Artificial intelligence (AI) is playing an increasingly important role in pharmacovigilance (PV), transforming how adverse drug reactions (ADRs) are detected, assessed, and reported. There are many tools coming up in the market having great claims on improvement of productivity, quality and turn around time in various pharmacovigilance processes like Intake, Literature Search and signal detection. Below are the areas where lot development is ongoing for AI enabled system.[6]

**can automatically extract and identify potential adverse events from:**

- **Electronic health records (EHRs)**
- Medical literature
- Social media and patient forums
- Spontaneous reporting databases

Natural Language Processing (NLP) tools are especially useful in analysing unstructured data (e.g., clinical notes, social media posts) for ADR signals.

**2. AI enabled chat boats for medical information centres**

AI chatbots are emerging as powerful tools for **patient-reported adverse drug reaction (ADR) collection**, making pharmacovigilance more **patient-centric, real-time, and scalable**. Here's a deep dive into how they work, their benefits, and examples:

- **Patient Interaction:** Chatbots interact with patients via web apps, mobile apps, or messaging platforms (e.g., WhatsApp, Facebook Messenger, SMS). They prompt patients to report side effects using natural language or guided forms.
- **Data Capture:** Collect structured and unstructured data: symptoms, timing, medication, dosage, demographics, medical history. NLP algorithms interpret and code the data using systems like MedDRA for regulatory reporting.
- **Automated Case Processing:** The chatbot flags serious ADRs for rapid follow-up. Can generate narrative summaries for PV case files. Integrates with safety databases (e.g., Argus, Veeva Vault Safety) for downstream processing
- Some benefits of using AI Chatbots are as below:
- **Increased Reporting Rates**: Patients are more likely to report ADRs via chatbots than traditional channels.
- **Faster Detection**: Real-time data collection accelerates signal detection.
- **Cost Efficiency**: Reduces need for call centres and manual data entry.
- **Enhanced Data Quality**: Consistent, structured data collection improves accuracy.
- **Patient Engagement**: Educates patients on drug safety and follow-up actions.[7,8]

**3. Case allocation and tracking in ICSR processing**

AI is playing an increasingly impactful role in case allocation and tracking in Individual Case Safety Report (ICSR) processing, helping pharmacovigilance (PV) teams manage high volumes of cases efficiently, accurately, and in compliance with regulatory timelines.
Here's how AI contributes to case allocation and tracking in ICSR workflows:

**A. AI in Case Allocation**

a. Automated Case Triage & Prioritization
AI systems analyse incoming ICSRs to:

- Determine seriousness, expectedness, and regulatory deadlines.
- Classify cases by source (e.g., spontaneous, literature, clinical trial) and region (to comply with local reporting rules).
- Predict complexity level based on data completeness, co-medications, and narratives.

b. Intelligent Workload Distribution
AI algorithms assess:

- Team member availability, current workload, expertise, and past performance.
- Allocates cases to ensure balanced workloads, adherence to SLA (Service Level Agreements), and efficient use of resources.

**c.** Escalation Management
AI can detect potential case processing bottlenecks (e.g., aging cases, approaching deadlines) and automatically escalate to managers or reassign cases for quicker action[9].

**B AI in Case Tracking**

a. Real-Time Dashboarding & Alerts
AI-powered dashboards track:

- Case status (intake, triage, assessment, submission stages).
- Turnaround times and regulatory timelines (e.g., 15-day, 7-day deadlines).
- AI detects processing delays and triggers alerts for proactive intervention.

b. Predictive Analytics
AI can forecast:

- Future case volumes (based on seasonality, product launches, campaigns).
- Potential resource gaps and processing delays, enabling better planning.

- Compliance risks for late reporting to regulators.

**c. Quality Monitoring**

AI systems audit cases in real time for completeness and consistency:

- Detect missing mandatory fields (e.g., reporter info, suspect drug).
- Flag duplicates, inconsistent coding, or narrative discrepancies.
- Provide feedback loops for continuous process improvement.

**4. Regulatory Intelligence mining**

Regulatory Intelligence (RI) mining is a critical function in pharmacovigilance (PV) that involves systematically gathering, analysing, and applying regulatory information to ensure compliance and optimize drug safety processes globally. With increasing complexity in global regulations, AI-powered regulatory intelligence mining is becoming essential for efficient PV operations. Below are some areas where AI can help:

**A. Monitoring and Tracking Global PV Regulations**

- Objective: Stay updated with evolving PV laws, guidelines, and submission requirements across countries (e.g., FDA, EMA, PMDA, CDSCO, MHRA).
- AI Role: Automatically scans regulatory agency websites, guidelines, legislation portals, and newsfeeds.
- Provides real-time alerts on changes (e.g., updated reporting timelines, new E2B standards).

**B. Impact Analysis and Compliance Planning**

- Objective: Assess how regulatory changes affect current PV processes and ensure timely adaptation.
- AI Role: Uses Natural Language Processing (NLP) to analyse new regulations, compare with existing policies, and suggest process updates or SOP revisions.
- Supports risk assessment and change management planning.[10]

**C. Automation of Literature and Document Review**

- Objective: Identify relevant guidelines, updates, and scientific publications impacting drug safety.
- AI Role: Mines PubMed, Embase, government portals using keyword extraction, topic modelling, and semantic search to extract actionable intelligence.
- Reduces manual review time and improves relevance filtering.

**D. Supporting Regulatory Submissions**

- Objective: Ensure accurate and timely submission of ICSRs, PSURs, DSURs, RMPs, and other PV deliverables.
- AI Role: Maps regulatory requirements to submission checklists, ensures regional compliance, and flags missing elements before filing.
- Ensures alignment with local PV reporting formats and deadlines.

**E. Competitive Intelligence**

- Objective: Understand how other companies handle PV compliance and monitor benchmark practices.
- AI Role: Mines public inspection reports, warning letters, and enforcement actions from agencies (e.g., FDA 483s).
- Highlights compliance trends and common pitfalls to avoid.

**F. Decision Support for PV Strategy**

- Objective: Enable proactive decision-making for global safety strategies, such as product launches, expansions, or audits.
- AI Role: Aggregates and presents regulatory landscapes by country or region, helping PV leaders assess regulatory risk profil[11]

**AI Technologies Used in Pharmacovigilance (PV)**

Pharmacovigilance involves detecting, assessing, understanding, and preventing adverse drug reactions (ADRs) and other drug-related problems. Modern PV increasingly relies on **Artificial Intelligence (AI)** to improve speed, accuracy, and efficiency.[12]

**1. Natural Language Processing (NLP)**

Used to analyze unstructured text data.

Applications:

- Extracting ADR information from:
  - Case reports (ICSRs)
  - Social media posts
  - Medical literature

**2. Machine Learning (ML)**

Learns patterns from data to support decision-making.

 ISSN: **3107-6513**

Applications:

- **Signal detection** (finding new safety issues)
- Classifying seriousness/severity of ADRs
- Predicting high-risk patients
- Detecting abnormal reporting patterns (quality checks)

Techniques:

- Logistic regression
- Random forest
- Gradient boosting
- SVM
- Clustering algorithms (k-means, DBSCAN)

**3. Deep Learning (DL)**

Superior for large and complex data.

Applications:

- Text mining from spontaneous reporting systems
- Image analysis (e.g., assessing drug packaging errors)
- Understanding high-dimensional EHR data
- Enhancing "causality assessment" of ADRs

Models:

LSTM, CNN, Transformers.

**4. Automation & Robotic Process Automation (RPA)**

Used for repetitive tasks.

Applications:

- Automatic case intake
- Data entry from emails, PDFs, call-center notes
- Tracking quality compliance activities
- Report generation for regulatory submissions

Benefits:

- Reduces manual workload
- Increases consistency and speed

**5. AI in Literature Surveillance**

Automated tools scan global literature for safety signals.

Functions:

- Automatic search of journals, case reports, conference papers
- Filtering relevant articles
- Extracting ADR-related content

Examples:

Embase AI search tools, PubMed AI filters, commercial safety platforms.

**6. AI in Social Media Monitoring**

AI tracks patient discussions related to drug side effects.

Applications:

- Detecting rare or early ADR signals
- Identifying misuse/abuse trends
- Monitoring vaccine safety conversations

AI tools classify texts, remove noise, and extract potential ADRs.[13,14]

**7. AI for Signal Management**

Improves the overall safety signal cycle:

Tasks Supported:

- Prioritization of signals
- Clustering similar reports
- Risk-benefit assessment using multi-source data
- Trend prediction of ADR reporting

Some platforms use **Bayesian neural networks** for advanced signal detection.

**8. AI in Causality Assessment**

Helps determine if a drug truly caused an ADR.

Methods:

- Predictive models using patient data
- Learning from historical ICSR decisions

- Algorithmic scoring (Naranjo-like automated tools)

**9. Chatbots for Patient Reporting & PV Support**

AI chatbots help collect ADR data from patients and HCPs.

Functions:

- Taking patient symptom reports
- Guiding users in ADR form submission
- Answering PV-related queries
- Multi-language support[15]

## APPLICATIONS OF AI IN PHARMACOVIGILANCE

### Adverse Event Detection and Reporting

Manually reporting Adverse Events (AEs) is often a slow process, resulting in significant delays in detecting potential safety issues. The vast amount of data from sources like electronic health records, social media and scientific literature can be overwhelming, resulting in under-reporting or missed cases. This data overload hinders the timely detection and reporting of crucial safety issues, underscoring the need for more efficient approaches.[16,17]

By processing large volumes of text data, NLP algorithms can detect mentions of drug names and associated adverse effects, often hidden in casual or non-standard language. This capability allows for the real-time monitoring of drug safety from social media platforms, providing a rich and timely source of information.[18,19]

Additionally, NLP helps in understanding patient sentiment and detecting emerging trends in drug safety, which might not be reported through traditional channels. Alfred Sorbello et al., introduced the SPINEL prototype, an AI-enabled software designed to enhance opioid pharmacovigilance by identifying ADEs from discharge summaries in Electronic Health Records (EHRs). This prototype aims to improve opioid drug safety and research activities at the FDA.[20]

SIGNAL DETECTION AND MANAGEMENT

Manual signal detection can be a lengthy process, often taking several months to identify new safety signals, which can result in delays in taking necessary actions.

Machine learning models can detect complex patterns and correlations within these datasets, often identifying signals earlier than conventional approaches. Additionally, AI-driven tools can continuously monitor and update safety profiles, providing real-time insights and facilitating prompt regulatory actions. This comprehensive approach improves drug safety and patient outcomes by ensuring timely detection and management of potential risks.8 According to J Praveen in 'Empowering Pharmacovigilance,' generative AI shows promise in enhancing drug safety monitoring by automating the creation of case reports, identifying adverse events and prioritising safety signals. It can analyse diverse data sources, including adverse event reports and electronic health records, to detect potential safety issues.[21]

However, human oversight and validation are crucial for interpreting and acting upon the insights generated. Integrating generative AI with traditional pharmacovigilance methods can improve signal detection, data analysis and risk assessment, leading to improved patient outcomes [22]

## RISK ASSESSMENT AND MITIGATION

Research by ClinChoice indicates that nearly 90% of pharmacovigilance activities are centered on post-market surveillance rather than on proactive risk assessment AI-powered risk prediction models and tools are essential in drug safety assessment and mitigation. [23]

## CASE PROCESSING AND TRIAGE

Manual case processing often results in considerable inefficiencies due to the time-consuming nature of tasks like data review, entry and analysis. Delays in triaging and prioritising cases create bottlenecks, further slowing down workflow.. AI technologies can automate the handling of individual case safety reports, significantly boosting performance compared to manual processing. For instance, the proposed design for case processing in the Pharmacovigilance Department of Indonesian vaccine companies has demonstrated a remarkable 219% increase in performance value when utilising AI technology.[24]

## POST-MARKET SURVEILLANCE

Monitoring the long-term safety of drugs post-market is challenging because of the extensive data produced from diverse sources like electronic health records, patient registries and spontaneous reporting systems. The diversity and volume of this information make it difficult to detect rare or long-

term adverse effects using traditional surveillance methods. AI's role in post-market surveillance is pivotal, offering tools and techniques to continuously monitor the safety of pharmaceutical products. AI can process real-time data from multiple sources, including electronic health records, social media and spontaneous reporting systems, to identify emerging safety issues and deliver prompt alerts.[25]

**SPONTANEOUS REPORTING SYSTEMS**

Spontaneous reporting systems like the FDA Adverse Event Reporting System (FAERS) are vital in pharmacovigilance, as they gather and analyze data on adverse drug reactions. AI methods automate the handling of Individual Case Safety Reports (ICSRs), substantially decreasing the manual effort needed for data entry and analysis. This automation enhances the speed and accuracy of detecting potential safety issues, allowing for quicker regulatory responses. Additionally, AI-driven data quality improvements ensure more reliable insights into drug safety. Robert Dal Pan et al., highlighted the increasing interest in utilising AI in PV, especially for processing and assessing ICSRs. (GPS) method. These techniques were applied to analyse associations between drugs, drug interactions and drug-related ADEs .[26]

**Benefits of AI in pharmacovigilance**

Leveraging AI in pharmacovigilance offers numerous advantages, transforming traditional drug safety workflows into more efficient and proactive processes. Here are the top five benefits.

1. Improved data analysis and signal detection

Pharmacovigilance AI solutions enable faster and more accurate analysis of large datasets from various sources, such as medical literature and social media. This leads to better signal detection for adverse drug reactions and potential safety issues, ensuring quicker risk responses.

2. Enhanced efficiency through automation

Implementing pharmacovigilance automation with AI significantly reduces manual data processing. This frees up time for pharmacovigilance professionals to focus on more strategic decision-making, streamlining workflows and boosting overall productivity.

3. Real-time monitoring and proactive risk management

AI-powered pharmacovigilance solutions provide real-time monitoring capabilities, allowing for the early detection of potential adverse effects. Predictive analytics help identify patterns, enabling proactive risk management before safety issues escalate.

4. Better compliance with regulatory requirements

Automated systems powered by AI ensure that safety reports are timely, complete, and in compliance with global regulatory standards. This reduces the risk of errors in documentation and allows for more consistent reporting, ultimately improving drug safety and company compliance.

5. Cost savings and resource optimization

The use of AI in pharmacovigilance reduces manual workload and operational costs. By enhancing data processing efficiency, companies can reallocate resources more effectively, improving productivity while maintaining safety and regulatory adherence.[27]

**The workflow of AI-enhanced pharmacovigilance**

AI is transforming pharmacovigilance processes by streamlining and automating key steps in the workflow. Here's an overview of a typical AI-enhanced pharmacovigilance workflow:

1. **Data collection and integration:** AI tools gather data from diverse sources, including medical records, social media, and patient reports, and then integrate it for comprehensive analysis.
2. **Signal detection and prioritization:** Machine learning algorithms analyze the data for potential safety signals and prioritize them based on severity and frequency, enhancing the efficiency of risk identification.
3. **Risk assessment and regulatory reporting:** AI systems assess the detected signals, evaluate associated risks, and generate reports for regulatory compliance, thereby automating pharmacovigilance reporting with AI for faster response times.

4. **Case management and follow-up:** Automated case processing ensures that adverse events are tracked, followed up, and managed throughout their lifecycle.
5. **Continuous monitoring and feedback:** AI-driven tools provide ongoing surveillance and feedback loops, constantly improving the accuracy of signal detection and risk management.[28]
6. **Challenges of implementing AI in pharmacovigilance**

Implementing AI in pharmacovigilance for drug safety faces some unique challenges that go beyond general AI adoption:

- **High volume of complex and unstructured data:** Pharmacovigilance relies on various data sources, including spontaneous reporting systems, social media, electronic health records, and literature.
- **Detection of rare adverse events:** AI models often require significant data to learn effectively. However, detecting rare adverse drug reactions can be difficult as there may be insufficient data for training, leading to reduced accuracy in identifying less common safety signals.
- **Bias in AI algorithms:** AI tools can develop biases based on the data they are trained on. For instance, under-reporting certain demographics or geographical regions can skew the model's ability to use AI for signal detection in pharmacovigilance systems accurately for those populations.[29]

**AI's importance in pharmacovigilance**

Drugs go through a lengthy and intricate clinical development procedure that typically involves a small number of precisely specified components and depends on short-term safety and efficacy. But after a medication is approved and submitted to the FDA, it is made accessible to the general public and used by a range of patient groups in real-world situations. The probability of previously unidentified adverse drug reactions (ADRs), drug interactions, and risk factors for CROP is greatly increased by this shift. Many of these risks may only become noticeable after extended use or in particular populations, such as children, pregnant women, or the elderly.. A strong medication monitoring system that not only guarantees early identification and action on medication errors but is also flexible enough to manage the growing amount and complexity of safety data is therefore desperately needed. In order to satisfy this need, there is increasing interest in promoting robotization and artificial intelligence (AI) to streamline case processing, improve signal detection, and facilitate prompt decision-making, all of which will eventually improve patient safety throughout the post-marketing stage.[30]

**Future Directions and Opportunities:**

A prospective analysis of how Generative AI (Gen AI) might advance pharmacovigilance procedures was also included in the materials and methods section. In order to enhance data security and facilitate real-time monitoring, it took into account integrating cutting-edge technologies like blockchain and the Internet of Things (IoT) with Gen AI. The part also emphasized methods to promote broader acceptance and more study in Gen AI applications in pharmacovigilance, emphasizing the value of cooperation and data exchange. Gen AI has already demonstrated a revolutionary impact on medication safety surveillance and monitoring. In the future, there will likely be chances to increase its capabilities and use cutting-edge technologies to transform pharmacovigilance processes. These developments have the potential to improve patient safety, expedite procedures, and encourage more effective and proactive methods of drug safety management.

For more accurate identification of adverse drug reactions (ADRs), big data analytics and real-world evidence (RWE) must be integrated. It is anticipated that genomic-informed personalized medicine would improve pharmacovigilance tactics according to patient profiles. Furthermore, chances for more thorough and consistent safety monitoring are presented by international cooperation and regulatory harmonization. Specialized pharmacovigilance techniques are required for emerging medicines, such as gene and biologic therapy, opening up new fields of expertise. There is a great deal of promise for enhancing ADR identification, monitoring, and management through the integration of AI into pharmacovigilance.

Large-scale datasets, such as social media posts, patient narratives, and electronic health records, can be analyzed using methods like natural language processing, machine learning, and deep learning to more accurately and instantly detect ADR signals.

By automating analysis and identifying intricate patterns that are beyond human comprehension, these tools assist in overcoming conventional pharmacovigilance difficulties, such as underreporting and delayed ADR identification. Additionally, AI can help with early high-risk patient identification and individualized risk

assessments, which will ultimately improve patient safety and allow for more successful regulatory actions. Pharmacovigilance is set to become more proactive as AI technology develops, enabling quicker worldwide reactions to new drug safety issues**.**

**application of AI-based optimization strategies in social media**

**The CASE STUDIES AND REAL-WORLD EXAMPLES platforms is covered in the paper:**

**A** study by Roche et al. highlighted the possibility for better pharmacovigilance by using AI and machine learning to evaluate social media user behavior indicators and detect ADEs with a 75% accuracy rate.

An overview of the medications used to treat COVID-19 is given in the text:

AI-based adaptive signal detection techniques were employed to find pulmonary Adverse Drug Events (pADEs) connected to hypertension drugs during the COVID- 19 pandemic. Significant differences across medicines were found in the study by Xu et al., which analyzed drug interactions and ADEs using sophisticated approaches like GPS, GLASSO clustering, and penalized regression. Table 1 highlights the benefits of AI-enhanced solutions over traditional pharmacovigilance in terms of accuracy, data entry, and reporting quality. While traditional approaches encounter errors and inconsistencies, artificial intelligence (AI) automates data extraction, cross-checks, and provides real-time monitoring.

**The difficulties and constraints of many facets of life are covered in the work**:

Securing high-quality, easily accessible data is a barrier for the use of AI in pharmacovigilance since biased and incomplete datasets can reduce the efficacy of machine learning models and make it more difficult to accurately identify adverse drug reactions (ADRs).[31]

**CONCLUSION**:

Pharmacovigilance, which keeps medications safe and effective for patients, has always been an essential component of healthcare. However, established methods of monitoring medication safety are falling behind as the complexity of current treatments increases, drug use increases globally, and vast volumes of health data are collected. Artificial Intelligence (AI) is proving to be a useful tool in this regard. AI can evaluate massive amounts of records, find trends that could otherwise go unnoticed, and swiftly identify safety hazards by utilizing technologies like machine learning, natural language processing, and predictive analytics. AI improves the intelligence, speed, and efficiency of pharmacovigilance in addition to automating jobs.The FDA's Sentinel Initiative, AstraZeneca's AI systems, and IBM Watson for Drug Safety are a few examples of how AI is being used to enhance safety monitoring and improve regulatory judgments. AI's capabilities are further increased by combining it with wearable technology, electronic medical records, and even social media data, enabling more immediate and individualized safety evaluations. Both patients and medical personnel gain from this, as it gives them the ability to take a more active part in their care.

**REFERENCE**

1. Sameena S, Shafi S, P.b D. Necessity, Importance, Future Aspects and Challenges of Pharmacovigilance. Asian J Pharm Res Dev. 2022;10(6):110-9.

2. Review on Concept of Pharmacovigilance. Int J Adv Res Sci Commun Technol. 2023;462-8.

3. Overview of Artificial Intelligence Technology.2023;6,111-9.

4. Tanani DS, Serragui S, Hammi S, Moussa LA, Soulaymani A, Soulaymani R, et al. National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program. Pan Afr Med J. 2017;26(48)

5. Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety | IntechOpen

2022:11:5

6. Sharma R, Nandave M, Kumar A. Introduction to Signal Detection in Pharmacovigilance. In: Nandave M, Kumar A, editors. Pharmacovigilance Essentials: Advances, Challenges and Global Perspectives, Singapore: Springer Nature; 2024, p. 333-45.

7. Bate, A., Lindquist, M., & Edwards, I. R. (2008). The application of knowledge discovery in databases to post-marketing drug safety: A review. Pharmacology & Therapeutics, 120(2), 81–95.

8.Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318

9. Bhatt A. Artificial intelligence in managing clinical trial design and conduct: Man and machine still on the learning curve? Perspect 2021;12:1-3.

10. Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf 2021;44:125-32.

11. Van Noorden R, Perkel JM. AI and science: What 1,600 researchers think. Nature 2023;621:672-5

12. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf 2008;31:2137.

13. Ralph Edwards I. Causality assessment in pharmacovigilance: Still a challenge. Drug Saf 2017;40:365-72.

14. Huysentruyt K, Kjoersvik O, Dobracki P, Savage E, Mishalov E, Cherry M, et al. Validating intelligent automation systems in pharmacovigilance: Insights from good manufacturing practices. Drug Saf 2021;44:261-72.

16. Mockute R, Desai S, Perera S, Assuncao B, Danysz K, Tetarenko N, et al. Artificial intelligence within pharmacovigilance: A means to identify cognitive services and the framework for their validation. Pharmaceut Med 2019;33:109-20.

17. Desai M. Pharmacovigilance and spontaneous adverse drug reaction reporting: Challenges and opportunities. Perspect Clin Res 2022;13:177-9. 17. Bhardwaj P. National quality registry for India: Need of the hour. Indian J Community Med 2022;47:157-8.

18. Chavhan AR, Uplenchwar PM. AI-Driven Signal Detection in Pharmacovigilance: Advancements, Challenges and Future Directions. Int J Pharm Pharm Res. 2024;30(5):99-119.

17. Praveen J. Empowering Pharmacovigilance: Unleashing the Potential of Generative AI in Drug Safety Monitoring. J Innov Appl Pharm Sci JIAPS. 2023;24-32.

19. ClinChoice. 2022 Pharmacovigilance: Literature Monitoring Best Practices.

20. Data Science and Artificial Intelligence: Unlocking new science insights

21. Irham A, Basri MH. Processing of Individual Case Safety Reports in The Pharmacovigilance Department of Indonesian Vaccine Companies. J World Sci. 2023 May 27;2(5):711-25.

22. Salvo F, Micallef J, Lahouegue A, Chouchana L, Létinier L, Faillie JL, et al. Will the future of pharmacovigilance be more automated? Expert Opin Drug Saf. 2023;22(7):541-8.

23. Ball R, Dal Pan G. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time? Drug Saf. 2022 May 1;45(5):429-38.

24.Bate A, Hobbiger SF. Artificial intelligence, real-world automation and the safety of medicines. Drug Saf 2021;44:125-32.

25. Henry S, Buchan K, Filannino M, Stubbs A, Uzuner O. 2018 n2c2 shared task on adverse drug events and medication extraction in electronic health records. J Am Med Inform Assoc 2020;27:3-12.

26. Luo Y, Thompson WK, Herr TM, Zeng Z, Berendsen MA, Jonnalagadda SR, et al. Natural language processing for EHR-Based pharmacovigilance: A structured review. Drug Saf 2017;40:1075-89.

27. Negi K, Pavuri A, Patel L, Jain C. A novel method for drug – Adverse event extraction using machine learning. Inf Med Unlocked 2019;17;100190.

28. Van Noorden R, Perkel JM. AI and science: What 1,600 researchers think. Nature 2023;621:672-5.

29. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf 2008;31:21-37.

30.WHO. (2021). Pharmacovigilance and artificial intelligence: Opportunities and challenges. World Health Organization.

31.Irham A, Basri MH. Processing of Individual Case Safety Reports in The Pharmacovigilance Department of Indonesian Vaccine Companies. J World Sci. 2023 May 27;2(5):711-25.